Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 9Urinary Bladder Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Neoplasms 2Esophageal Neoplasms 2Colorectal Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Turcot syndrome 1Thyroid Neoplasms 1Tertiary Lymphoid Structures 1Sarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms by Site 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Muscle Invasive Bladder Urothelial Carcinoma 1Multiple Myeloma 1Microsatellite Instability 1Melanoma, Cutaneous Malignant 1

Interventions

Specimen Handling 5Nivolumab 4Magnetic Resonance Spectroscopy 4cabozantinib 3Gemcitabine 3enfortumab vedotin 2Ipilimumab 2Carboplatin 2CTLA-4 Antigen 2Biopsy 2trastuzumab deruxtecan 1relatlimab 1pembrolizumab 1eribulin 1erdafitinib 1avelumab 1atezolizumab 1Lenalidomide 1Doxorubicin 1Contrast Media 1Cisplatin 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urethral Neoplasms × relatlimab × 90 days × Clear all
NCT04953104 2026-04-15

ARID1A and/or KDM6A Mutation and CXCL13 Expression

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
6 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡